Three-Dimensional Blood-Brain Barrier Model for in vitro Studies of Neurovascular Pathology

Blood–brain barrier (BBB) pathology leads to neurovascular disorders and is an important target for therapies. However, the study of BBB pathology is difficult in the absence of models that are simple and relevant. In vivo animal models are highly relevant, however they are hampered by complex, multi-cellular interactions that are difficult to decouple. In vitro models of BBB are simpler, however they have limited functionality and relevance to disease processes. To address these limitations, we developed a 3-dimensional (3D) model of BBB on a microfluidic platform. We verified the tightness of the BBB by showing its ability to reduce the leakage of dyes and to block the transmigration of immune cells towards chemoattractants. Moreover, we verified the localization at endothelial cell boundaries of ZO-1 and VE-Cadherin, two components of tight and adherens junctions. To validate the functionality of the BBB model, we probed its disruption by neuro-inflammation mediators and ischemic conditions and measured the protective function of antioxidant and ROCK-inhibitor treatments. Overall, our 3D BBB model provides a robust platform, adequate for detailed functional studies of BBB and for the screening of BBB-targeting drugs in neurological diseases.

[1]  P. Couraud,et al.  Rat Brain Endothelial Cell Lines for the Study of Blood–Brain Barrier Permeability and Transport Functions , 2005, Cellular and Molecular Neurobiology.

[2]  I. Krizbai,et al.  Activation of Cannabinoid Receptor 2 Attenuates Leukocyte–Endothelial Cell Interactions and Blood–Brain Barrier Dysfunction under Inflammatory Conditions , 2012, The Journal of Neuroscience.

[3]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[4]  M. Plotkine,et al.  Antioxidant strategies in the treatment of stroke. , 2005, Free radical biology & medicine.

[5]  M. Tansey,et al.  TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. , 2011, Advances in experimental medicine and biology.

[6]  H. Matsui,et al.  Tumor necrosis factor-alpha-induced cytokine-induced neutrophil chemoattractant-1 (CINC-1) production by rat gastric epithelial cells: role of reactive oxygen species and nuclear factor-kappaB. , 2004, The Journal of pharmacology and experimental therapeutics.

[7]  Karin E. Sandoval,et al.  Blood-brain barrier tight junction permeability and ischemic stroke , 2008, Neurobiology of Disease.

[8]  R. Sidman,et al.  Communication via gap junctions underlies early functional and beneficial interactions between grafted neural stem cells and the host , 2010, Proceedings of the National Academy of Sciences.

[9]  J. Siliciano,et al.  Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia , 1986, The Journal of cell biology.

[10]  S. Rohrbach,et al.  Hypoxia–reoxygenation‐induced endothelial barrier failure: role of RhoA, Rac1 and myosin light chain kinase , 2013, The Journal of physiology.

[11]  Hyun Seok Song,et al.  SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier , 2003, Nature Medicine.

[12]  J. Weber,et al.  Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. , 2008, Current medicinal chemistry.

[13]  I. Wilhelm,et al.  In vitro models of the blood-brain barrier. , 2011, Acta neurobiologiae experimentalis.

[14]  B. Zlokovic The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[15]  B. Zlokovic,et al.  Central nervous system pericytes in health and disease , 2011, Nature Neuroscience.

[16]  B. Hyman,et al.  Microfluidic Chemotaxis Platform for Differentiating the Roles of Soluble and Bound Amyloid-β on Microglial Accumulation , 2013, Scientific Reports.

[17]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[18]  A. Facchini,et al.  IL-17, IL-1β and TNF-α stimulate VEGF production by dedifferentiated chondrocytes , 2004 .

[19]  M. Gassmann,et al.  Astrocytes and Pericytes Differentially Modulate Blood—Brain Barrier Characteristics during Development and Hypoxic Insult , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Luca Cucullo,et al.  In vitro blood-brain barrier models: current and perspective technologies. , 2012, Journal of pharmaceutical sciences.

[21]  H. Matsui,et al.  Tumor Necrosis Factor-α-Induced Cytokine-Induced Neutrophil Chemoattractant-1 (CINC-1) Production by Rat Gastric Epithelial Cells: Role of Reactive Oxygen Species and Nuclear Factor-κB , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  Christopher S. Stevenson,et al.  Comprehensive gene expression profiling of rat lung reveals distinct acute and chronic responses to cigarette smoke inhalation. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[23]  R. Takahashi,et al.  Synergistic induction of CX3CL1 by TNF alpha and IFN gamma in osteoblasts from rheumatoid arthritis: involvement of NF-kappa B and STAT-1 signaling pathways , 2008, Journal of inflammation research.

[24]  Luca Cucullo,et al.  Development of a Humanized In Vitro Blood–Brain Barrier Model to Screen for Brain Penetration of Antiepileptic Drugs , 2007, Epilepsia.

[25]  P. Young,et al.  Tumor necrosis factor-alpha expression in ischemic neurons. , 1994, Stroke.

[26]  Donald W. Miller,et al.  Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. , 1999, Life sciences.

[27]  C. Iadecola Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[28]  E. Tutar,et al.  Protective effects of Y-27632 on hypoxia/reoxygenation-induced intestinal injury in newborn rats. , 2011, Journal of pediatric surgery.

[29]  J. Larrick,et al.  Cytotoxic mechanism of tumor necrosis factor‐α , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  P. Lapchak A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? , 2010, Expert opinion on pharmacotherapy.

[31]  J. An,et al.  Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. , 2008, Blood.

[32]  T. Davis,et al.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? , 2014, Current pharmaceutical design.

[33]  Yoav Mayshar,et al.  Mfsd2a is critical for the formation and function of the blood–brain barrier , 2014, Nature.

[34]  Hanseup Kim,et al.  Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). , 2012, Lab on a chip.

[35]  J. Mieyal,et al.  Glutathione Supplementation Potentiates Hypoxic Apoptosis by S-Glutathionylation of p65-NFκB* , 2007, Journal of Biological Chemistry.

[36]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[37]  J. Haorah,et al.  Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions , 2006, Journal of Neuroimmune Pharmacology.

[38]  G. Bu,et al.  TIMP-1 attenuates blood–brain barrier permeability in mice with acute liver failure , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[40]  P. Bath,et al.  Inhibition of Rho‐kinase protects cerebral barrier from ischaemia‐evoked injury through modulations of endothelial cell oxidative stress and tight junctions , 2014, Journal of neurochemistry.

[41]  C. Wira,et al.  CCL20/Macrophage Inflammatory Protein 3α and Tumor Necrosis Factor Alpha Production by Primary Uterine Epithelial Cells in Response to Treatment with Lipopolysaccharide or Pam3Cys , 2005, Infection and Immunity.

[42]  H. Sarau,et al.  The FASEB Journal express article 10.1096/fj.03-0170fje. Published online Novermber 3, 2003. Regulation of TNF-α and IFN-γ induced CXCL10 , 2022 .

[43]  Alon Friedman,et al.  Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury , 2010, Nature Reviews Neurology.

[44]  D. Groothuis,et al.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.

[45]  A. Berg,et al.  BBB ON CHIP: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function , 2013, Biomedical microdevices.

[46]  Steven Warach,et al.  Early blood–brain barrier disruption in human focal brain ischemia , 2004, Annals of neurology.

[47]  D. Muller,et al.  An in vitro blood-brain barrier model: cocultures between endothelial cells and organotypic brain slice cultures. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.